These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 17532523)

  • 1. Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies.
    Pockros PJ; Guyader D; Patton H; Tong MJ; Wright T; McHutchison JG; Meng TC
    J Hepatol; 2007 Aug; 47(2):174-82. PubMed ID: 17532523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial.
    Pol S; Ghalib RH; Rustgi VK; Martorell C; Everson GT; Tatum HA; Hézode C; Lim JK; Bronowicki JP; Abrams GA; Bräu N; Morris DW; Thuluvath PJ; Reindollar RW; Yin PD; Diva U; Hindes R; McPhee F; Hernandez D; Wind-Rotolo M; Hughes EA; Schnittman S
    Lancet Infect Dis; 2012 Sep; 12(9):671-7. PubMed ID: 22714001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, pharmacokinetics and pharmacodynamics of the oral toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis C.
    Lawitz E; Gruener D; Marbury T; Hill J; Webster L; Hassman D; Nguyen AH; Pflanz S; Mogalian E; Gaggar A; Massetto B; Subramanian GM; McHutchison JG; Jacobson IM; Freilich B; Rodriguez-Torres M
    Antivir Ther; 2015; 20(7):699-708. PubMed ID: 25105516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV.
    Bergmann JF; de Bruijne J; Hotho DM; de Knegt RJ; Boonstra A; Weegink CJ; van Vliet AA; van de Wetering J; Fletcher SP; Bauman LA; Rahimy M; Appleman JR; Freddo JL; Janssen HL; Reesink HW
    Aliment Pharmacol Ther; 2011 Aug; 34(4):443-53. PubMed ID: 21707679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical resiquimod dosing regimens in patients with multiple actinic keratoses: a multicentre, partly placebo-controlled, double-blind clinical trial.
    Stockfleth E; Hofbauer GFL; Reinhold U; Popp G; Hengge UR; Szeimies RM; Brüning H; Anliker M; Hunger T; Dummer R; Ulrich C; Kenzelmann R; Surber C; French LE
    Br J Dermatol; 2019 Feb; 180(2):297-305. PubMed ID: 30171698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1.
    Izumi N; Yokosuka O; Kawada N; Osaki Y; Yamamoto K; Sata M; Ishikawa H; Ueki T; Hu W; McPhee F; Hughes EA; Kumada H
    Antivir Ther; 2014; 19(5):501-10. PubMed ID: 24451151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial.
    Gane EJ; Roberts SK; Stedman CA; Angus PW; Ritchie B; Elston R; Ipe D; Morcos PN; Baher L; Najera I; Chu T; Lopatin U; Berrey MM; Bradford W; Laughlin M; Shulman NS; Smith PF
    Lancet; 2010 Oct; 376(9751):1467-75. PubMed ID: 20951424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study.
    Forestier N; Larrey D; Guyader D; Marcellin P; Rouzier R; Patat A; Smith P; Bradford W; Porter S; Blatt L; Seiwert SD; Zeuzem S
    J Hepatol; 2011 Jun; 54(6):1130-6. PubMed ID: 21145848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy with TLR7 agonists induces lymphopenia: correlating pharmacology to mechanism in a mouse model.
    Perkins H; Khodai T; Mechiche H; Colman P; Burden F; Laxton C; Horscroft N; Corey T; Rodrigues D; Rawal J; Heyen J; Fidock M; Westby M; Bright H
    J Clin Immunol; 2012 Oct; 32(5):1082-92. PubMed ID: 22476912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal dosing frequency of pegylated interferon alfa-2b monotherapy for chronic hepatitis C virus infection.
    Lurie Y; Rouzier-Panis R; Webster GJ; Dusheiko GM; Laughlin M; Jackson ML; Oren R
    Clin Gastroenterol Hepatol; 2005 Jun; 3(6):610-5. PubMed ID: 15952104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.
    Manns M; Pol S; Jacobson IM; Marcellin P; Gordon SC; Peng CY; Chang TT; Everson GT; Heo J; Gerken G; Yoffe B; Towner WJ; Bourliere M; Metivier S; Chu CJ; Sievert W; Bronowicki JP; Thabut D; Lee YJ; Kao JH; McPhee F; Kopit J; Mendez P; Linaberry M; Hughes E; Noviello S;
    Lancet; 2014 Nov; 384(9954):1597-605. PubMed ID: 25078304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection.
    Suzuki F; Toyota J; Ikeda K; Chayama K; Mochida S; Hayashi N; Ishikawa H; Miyagoshi H; Hu W; McPhee F; Hughes EA; Kumada H
    Antivir Ther; 2014; 19(5):491-9. PubMed ID: 24451122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-treatment with prednisolone does not improve the efficacy of subsequent alpha interferon therapy in chronic hepatitis C.
    Guilera M; Forns X; Torras X; Enríquez J; Coll S; Solà R; Morillas R; Planas R; Ampurdanès S; Soler M; Costa J; Sáiz JC; Sánchez-Tapias JM; Rodés J
    J Hepatol; 2000 Jul; 33(1):135-41. PubMed ID: 10905597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults.
    Sauder DN; Smith MH; Senta-McMillian T; Soria I; Meng TC
    Antimicrob Agents Chemother; 2003 Dec; 47(12):3846-52. PubMed ID: 14638493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-α suppressed granulocyte colony stimulating factor production is reversed by CL097, a TLR7/8 agonist.
    Tajuddin T; Ryan EJ; Norris S; Hegarty JE; O'Farrelly C
    J Gastroenterol Hepatol; 2010 Dec; 25(12):1883-90. PubMed ID: 21092001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection.
    Gane EJ; Lim YS; Gordon SC; Visvanathan K; Sicard E; Fedorak RN; Roberts S; Massetto B; Ye Z; Pflanz S; Garrison KL; Gaggar A; Mani Subramanian G; McHutchison JG; Kottilil S; Freilich B; Coffin CS; Cheng W; Kim YJ
    J Hepatol; 2015 Aug; 63(2):320-8. PubMed ID: 25733157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.
    Lawitz E; Lalezari JP; Hassanein T; Kowdley KV; Poordad FF; Sheikh AM; Afdhal NH; Bernstein DE; Dejesus E; Freilich B; Nelson DR; Dieterich DT; Jacobson IM; Jensen D; Abrams GA; Darling JM; Rodriguez-Torres M; Reddy KR; Sulkowski MS; Bzowej NH; Hyland RH; Mo H; Lin M; Mader M; Hindes R; Albanis E; Symonds WT; Berrey MM; Muir A
    Lancet Infect Dis; 2013 May; 13(5):401-8. PubMed ID: 23499158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus.
    McHutchison JG; Bacon BR; Gordon SC; Lawitz E; Shiffman M; Afdhal NH; Jacobson IM; Muir A; Al-Adhami M; Morris ML; Lekstrom-Himes JA; Efler SM; Davis HL
    Hepatology; 2007 Nov; 46(5):1341-9. PubMed ID: 17929306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
    Everson GT; Sims KD; Rodriguez-Torres M; Hézode C; Lawitz E; Bourlière M; Loustaud-Ratti V; Rustgi V; Schwartz H; Tatum H; Marcellin P; Pol S; Thuluvath PJ; Eley T; Wang X; Huang SP; McPhee F; Wind-Rotolo M; Chung E; Pasquinelli C; Grasela DM; Gardiner DF
    Gastroenterology; 2014 Feb; 146(2):420-9. PubMed ID: 24184132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study.
    Zein NN;
    J Hepatol; 2005 Mar; 42(3):315-22. PubMed ID: 15791697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.